The latest in the drama has been Pfizer losing the patent infringement case it had filed against Ranbaxy’s calcium salt ‘Atorvastatin’ – a generic adaptation of ‘Lipitor’. It is no doubt a sweet victory for Ranbaxy, as R. Deshmukh, Senior VP, Global Intellectual Property, Ranbaxy, Sweetly says, “We are pleased by the court’s decision.” Ranbaxy has been allowed to continue selling the salt (though for six more months only), but its real victory has been that Lipitor’s patent protection period, which was to expire in June 2011, has now been reduced to March 2010.
For once, it is an Indian company in the pharmaceutical sector that is giving American multinationals a run for their pennies, and in their home markets!
For complete IIPM article click here
Source:- IIPM Editorial
Visit also:- IIPM Publication, Business & Economy & Arindam Chaudhuri Initiative
For once, it is an Indian company in the pharmaceutical sector that is giving American multinationals a run for their pennies, and in their home markets!
For complete IIPM article click here
Source:- IIPM Editorial
Visit also:- IIPM Publication, Business & Economy & Arindam Chaudhuri Initiative
No comments:
Post a Comment